Rare Disease

Astrosalva Names Sarepta's Wendy Erler First Strategic Advisor

Image
Astrosalva Names Sarepta's Wendy Erler First Strategic Advisor

SAN MATEO – November 05, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), has appointed Wendy Erler, Senior Vice President of Patient Affairs at Sarepta Therapeutics, as the first member of its Strategic Advisory Board.

Erler to steer patient engagement and trial planning at Astrosalva

Erler will advise on patient and community engagement strategy. Her remit includes working with existing community natural history registries and bringing patient and caregiver perspectives into future clinical trial planning.

Co-founder and CEO Paul Schmidt said the order of announcements is deliberate: Erler is the first advisor named, because the company wants families to know it is being built around patients and their communities.

INOVIO to Present INO-D001 Hemophilia A Program at Montreal Workshop

Image
INOVIO to Present INO-D001 Hemophilia A Program at Montreal Workshop

PLYMOUTH MEETING – November 03, 2026 -- INOVIO (NASDAQ: INO) will present its INO-D001 program for Hemophilia A at the World Federation of Hemophilia New Technology & Gene Therapy (NTGT) Workshop in Montreal on Thursday, Nov. 12, extending its DNA medicine work beyond HPV-related diseases, cancer and infectious diseases.

INOVIO schedules rare disease presentation in New York for Nov. 8

The company will speak at the Soft Bones Third International Scientific Meeting on Hypophosphatasia in New York on Sunday, Nov. 8. Its presentation is titled "Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine."

Montreal workshop session focuses on INO-D001 for Hemophilia A

The Nov. 12 presentation at the WFH NTGT Workshop is dedicated to INO-D001 in Hemophilia A. The two appearances are four days apart, on Nov. 8 and Nov. 12.

Zhimeng Completes 255-Patient Enrollment in Pivotal ALS Trial

Shanghai – October 31, 2026 -- Shanghai Zhimeng Biopharma has completed enrollment of 255 patients in the pivotal Phase 2/3 trial of CB03-154 for amyotrophic lateral sclerosis (ALS), moving the potassium channel opener toward topline data and a possible new drug application in China.

Trial runs at 15 Chinese centers with a Week 39 primary endpoint

The study is led by Professor Fan Dongsheng of the 3rd Affiliated Hospital of Peking University and spans 15 clinical research centers in Mainland China. Its primary efficacy endpoint is the change from baseline in ALSFRS-R score at Week 39. China's Center for Drug Evaluation (CDE) cleared the Phase 2/3 study in July 2025. The U.S. FDA granted CB03-154 Orphan Drug Designation in October 2023.

Astrosalva Launches With Unravel as Founding Partner for Rare Brain Diseases

Image
Astrosalva Launches With Unravel as Founding Partner for Rare Brain Diseases

SAN MATEO – October 29, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech, has launched with Unravel Biosciences as its founding development partner to pursue treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD). Unravel co-founder and CEO Richard Novak, PhD, has joined Astrosalva's board of directors.

Astrosalva widens its focus from Alexander disease to cALD

Both conditions are rare genetic diseases affecting the brain's white matter. In children, cALD can progress rapidly and often leads to total disability within a few years. MedlinePlus puts the prevalence of X-linked adrenoleukodystrophy, the genetic condition behind cALD, at 1 in 15,000 people worldwide. Ionis Pharmaceuticals estimates that Alexander disease affects about 1 in 1 to 3 million people worldwide.

Atrium Doses First Patient in Phase 1/2 ATR 1072 PRKAG2 Trial

Image
Atrium Doses First Patient in Phase 1/2 ATR 1072 PRKAG2 Trial

San Diego – October 29, 2026 -- Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in Corventis, a Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome, and expects initial proof-of-concept data in the second half of 2027.

Corventis will enroll about 37 participants in two parts

The open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of ATR 1072. Part A uses multiple ascending dose cohorts to characterize safety and support dose selection. Part B is a single-arm expansion cohort at the recommended Phase 2 dose, assessing efficacy trends in cardiac structure and function.

The primary endpoint is the incidence of treatment-emergent adverse events. Secondary and exploratory endpoints include PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics.

Cadrenal's CAD-1005 Cuts Thrombotic Events 25% in HIT Phase 2

PARIS – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reported that its 12-lipoxygenase inhibitor CAD-1005 reduced new or worsening thrombotic events by more than 25 percentage points versus placebo in a Phase 2 trial in heparin-induced thrombocytopenia (HIT), with 50% of treated patients affected versus more than 75% on placebo. The data were presented as one of three late-breaking abstracts at the ISTH 2026 Congress in Paris.

Trial is first randomized, blinded, placebo-controlled study in HIT

Principal Investigator Dr. Steven E. McKenzie delivered the oral presentation, which Cadrenal describes as the first randomized, blinded, placebo-controlled trial in HIT patients. CAD-1005 was formerly known as VLX-1005. The study was not sufficiently powered for statistical significance.

FDA Grants Orphan Drug Status to Vivacta Bio's In Vivo CAR-T GT801

Image
FDA Grants Orphan Drug Status to Vivacta Bio's In Vivo CAR-T GT801

Shanghai – October 17, 2026 -- The U.S. Food and Drug Administration has granted Orphan Drug Designation to GT801, the lead in vivo CAR-T candidate of Vivacta Biotechnology (Shanghai) Co., Ltd., for autoimmune hemolytic anemia (AIHA). Vivacta Bio was spun out of Beijing Grit Biotherapeutics' in vivo CAR-T platform on June 25, 2025.

Designation opens tax credits, fee exemption and seven-year exclusivity

Sponsors of designated products may be eligible for tax credits on qualified clinical trial expenses and an exemption from marketing application user fees. They may also receive seven years of orphan drug market exclusivity after marketing approval, subject to applicable requirements.

Paradigm Therapeutics Named Prix Galien Finalist for Second Year

Image
Paradigm Therapeutics Named Prix Galien Finalist for Second Year

Mount Pleasant, S.C. – October 14, 2026 -- Paradigm Therapeutics, Inc. has been named a finalist for the 2026 Prix Galien USA "Best Start-Up" Award, its second consecutive nomination after being a nominee in 2025.

The clinical-stage biopharmaceutical company is developing SD-101 (ZorblesiaTM), a topical cream for wounds and lesions across the entire skin surface in patients with Epidermolysis Bullosa (EB). The Galien Foundation manages the awards, which will be presented on October 14, 2026, at the American Museum of Natural History in New York City.

Keenova Presents TERLIVAZ Data for Transplant-Ineligible HRS-AKI

Image
Keenova Presents TERLIVAZ Data for Transplant-Ineligible HRS-AKI

Dublin – October 13, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.

Ten-author analysis targets liver transplant-ineligible patients

The presentation is titled "Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial." Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, is the presenting author. Nine co-authors are listed, including Kavish Patidar, Kevin Regner and Nneka N. Ufere.

Abbisko's Lavengratinib Shows 2.4cm/Year Growth Gain in Achondroplasia Trial

Image
Abbisko's Lavengratinib Shows 2.4cm/Year Growth Gain in Achondroplasia Trial

Shanghai – September 21, 2026 -- Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) reported that its oral FGFR2/3 inhibitor lavengratinib achieved a mean increase of 2.4 cm/year in annualized height velocity among children with achondroplasia in the lowest-dose cohort of a Phase II trial, with a 100% responder rate.

Seven children in the first dose cohort completed six months of treatment with no serious adverse events

All seven participants aged 6 to 12 in cohort 1 of the ABSK061-202 study received lavengratinib at 0.064 mg/kg once daily for 27 weeks. Responders were defined as achieving at least a 25% improvement in annualized height velocity from baseline, a threshold every participant in the cohort met.